靶向细胞周期抗肿瘤药物研究进展

[3]DIAZ-MORALLI S, TARRADO-CASTELLARNAU M, MIRANDA A, et al. Targeting cell cycle regulation in cancer therapy[J]. Pharmacol Ther, 2013, 138(2): 255-271. DOI:10.1016/j.pharmthera.2013.01.011

[4]MATTHEWS H K, BERTOLI C, DE BRUIN R A M. Cell cycle control in cancer[J]. Nat Rev Mol Cell Biol, 2022, 23(1): 74-88. DOI:10.1038/s41580-021-00404-3

[5]BYBEE A, THOMAS N S. Cell cycle regulation[J]. Blood Rev, 1991, 5(3): 177-192. DOI:10.1016/0268-960x(91)90042-5

[6]HAMILTON E, INFANTE J R. Targeting CDK4/6 in patients with cancer[J]. Cancer Treat Rev, 2016, 45: 129-138. DOI:10.1016/j.ctrv.2016.03.002

[7]O'LEARY B, FINN R S, TURNER N C. Treating cancer with selective CDK4/6 inhibitors[J]. Nat Rev Clin Oncol, 2016, 13(7): 417-430. DOI:10.1038/nrclinonc.2016.26

[8]范丽萍, 焦园园, 郭子寒, 等. 新型CDK4/6抑制剂palbociclib[J]. 中国新药杂志, 2015, 24(19): 2161-2163+2202.

[9]王业涤, 刘艳佳, 陈博, 等. 阿贝西利药物的研究进展[J]. 化工时刊, 2022, 36(12): 27-28+44.

[10]高萱, 宋德旭, 窦鹏. 达尔西利的研究进展[J]. 广东化工, 2023, 50(16): 80-81+105.

[11]FDA批准ribociclib治疗乳腺癌[J]. 世界临床药物, 2018, 39(08): 582.

[12]ISMAIL R K, VAN BREESCHOTEN J, WOUTERS M, et al. Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer[J]. Breast, 2021, 60: 263-271. DOI:10.1016/j.breast.2021.10.005

[13]Dalpiciclib Extends Progression-Free Survival in HR+/HER2- Advanced Breast Cancer[J]. Oncologist, 2021, 26(Suppl 3): S9-S10. DOI:10.1002/onco.13816

[14]BRAAL C L, JONGBLOED E M, WILTING S M, et al. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences[J]. Drugs, 2021, 81(3): 317-331. DOI:10.1007/s40265-020-01461-2

[15]TOLANEY S M, SAHEBJAM S, LE RHUN E, et al. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer[J]. Clin Cancer Res, 2020, 26(20): 5310-5319. DOI:10.1158/1078-0432.CCR-20-1764

[16]TRIPATHY D, IM S A, COLLEONI M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7): 904-915. DOI:10.1016/S1470-2045(18)30292-4

[17]尤梅桂, 蔡禹, 吴雅茗, 等. 细胞周期相关激酶及其抑制剂抗肿瘤作用的研究进展[J]. 临床合理用药, 2025, 18(06): 172-176.

[18]苏晓路, 张煦, 田卫华. Aurora-A在细胞有丝分裂中作用及与肿瘤关系[J]. 青岛大学医学院学报, 2008, 44(5): 465-467+470.

[19]马澜婧, 杜海琛, 张百红. 极光激酶B抑制剂的研究进展[J]. 现代药物与临床, 2023, 38(10): 2620-2630.

[20]SCHWARTZ G K, CARVAJAL R D, MIDGLEY R, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors[J]. Invest New Drugs, 2013, 31(2): 370-380. DOI:10.1007/s10637-012-9850-6

[21]TAYYAR Y, JUBAIR L, FALLAHA S, et al. Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data[J]. Crit Rev Oncol Hematol, 2017, 119: 59-65. DOI:10.1016/j.critrevonc.2017.10.006

[22]ADHIKARI B, BOZILOVIC J, DIEBOLD M, et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase[J]. Nat Chem Biol, 2020, 16(11): 1179-1188. DOI:10.1038/s41589-020-00652-y

[23]KIM T. Recent Progress on the Localization of PLK1 to the Kinetochore and Its Role in Mitosis[J]. Int J Mol Sci, 2022, 23(9): 5002. DOI:10.3390/ijms23095002

[24]FANG L, LIU Q, CUI H, et al. Bioinformatics Analysis Highlight Differentially Expressed CCNB1 and PLK1 Genes as Potential Anti-Breast Cancer Drug Targets and Prognostic Markers[J]. Genes (Basel), 2022, 13(4): 654. DOI:10.3390/genes13040654

[25]SALAMA M E, KHAIRY D A. Polo-Like Kinase 1(PLK1) Immunohistochemical Expression in Triple Negative Breast Carcinoma: A Probable Therapeutic Target[J]. Asian Pac J Cancer Prev, 2021, 22(12): 3921-3925. DOI:10.31557/APJCP.2021.22.12.3921

[26]信欣, 冯畅, 王诗慧, 等. 作用于ATP结合区域的PLK1抑制剂研究进展[J]. 中国药物化学杂志, 2021, 31(07): 532-540.

[27]黄道伟, 杨晓聪, 张越, 等. 多肽类PLK1-PBD抑制剂的研究进展[J]. 中国药物化学杂志, 2022, 32(04): 305-313.

[28]DÖHNER H, LÜBBERT M, FIEDLER W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy[J]. Blood, 2014, 124(9): 1426-1433. DOI:10.1182/blood-2014-03-560557

[29]AHN D H, RIDINGER M, CANNON T L, et al. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial[J]. J Clin Oncol, 2025, 43(7): 840-851. DOI:10.1200/JCO.24.00915

[30]NAVADA S C, SILVERMAN L R. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes[J]. Expert Rev Anticancer Ther, 2016, 16(8): 805-810. DOI:10.1080/14737140.2016.1199271

[31]REINHARDT H C, YAFFE M B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2[J]. Curr Opin Cell Biol, 2009, 21(2): 245-255. DOI:10.1016/j.ceb.2009.01.018

[32]岳厚汝, 薛佳兴, 易俊希, 等. Chk1及其抑制剂在肿瘤中的作用[J]. 生命的化学, 2020, 40(10): 1738-1750.

[33]GIUDICE E, HUANG T T, NAIR J R, et al. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial[J]. Nat Commun, 2024, 15(1): 2805. DOI:10.1038/s41467-024-47103-z

[34]JONES R, PLUMMER R, MORENO V, et al. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer[J]. Clin Cancer Res, 2023, 29(2): 331-340. DOI:10.1158/1078-0432.CCR-22-2276

[35]HUFFMAN B M, FENG H, PARMAR K, et al. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma[J]. Clin Cancer Res, 2023, 29(24): 5047-5056. DOI:10.1158/1078-0432.CCR-23-1280

[36]IORNS E, LORD C J, GRIGORIADIS A, et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets[J]. PLoS One, 2009, 4(4): e5120. DOI:10.1371/journal.pone.0005120

[37]MASAKI T, SHIRATORI Y, RENGIFO W, et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis[J]. Hepatology, 2003, 37(3): 534-543. DOI:10.1053/jhep.2003.50112

[38]SLIPICEVIC A, HOLTH A, HELLESYLT E, et al. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions[J]. Gynecol Oncol, 2014, 135(1): 118-124. DOI:10.1016/j.ygyno.2014.07.102

[39]FUKUDA K, TAKEUCHI S, ARAI S, et al. Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations[J]. Cell Rep Med, 2024, 5(6): 101578. DOI:10.1016/j.xcrm.2024.101578

[40]LEIJEN S, VAN GEEL R M, PAVLICK A C, et al. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors[J]. J Clin Oncol, 2016, 34(36): 4371-4380. DOI:10.1200/JCO.2016.67.5991

[41]DIAB A, KAO M, KEHRLI K, et al. Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition[J]. Mol Cancer Res, 2019, 17(5): 1115-1128. DOI:10.1158/1541-7786.MCR-18-0460

[42]SCHUTTE T, EMBABY A, STEEGHS N, et al. Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review[J]. Cancer Treat Rev, 2023, 115: 102531. DOI:10.1016/j.ctrv.2023.102531

[43]PREVITALI V, BAGNOLINI G, CIAMARONE A, et al. New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives[J]. J Med Chem, 2024, 67(14): 11488-11521. DOI:10.1021/acs.jmedchem.4c00123

版权与开放获取声明

作为一本开放获取的学术期刊，所有文章均遵循 Creative Commons Attribution 4.0 International License (CC BY 4.0) 协议发布，允许用户在署名原作者的前提下自由共享与再利用内容。所有文章均可免费供读者和机构阅读、下载、引用与传播，EWA Publishing 不会通过期刊的出版发行向读者或机构收取任何费用。